Show simple item record

dc.contributor.authorWakhloo, Ajay K.
dc.contributor.authorGounis, Matthew J.
dc.contributor.authorSurpass Study Group
dc.date2022-08-11T08:10:47.000
dc.date.accessioned2022-08-23T17:19:44Z
dc.date.available2022-08-23T17:19:44Z
dc.date.issued2015-01-01
dc.date.submitted2017-05-24
dc.identifier.citationAJNR Am J Neuroradiol. 2015 Jan;36(1):98-107 Aug 14. <a href="https://doi.org/10.3174/ajnr.A4078">Link to article on publisher's site</a>
dc.identifier.issn0195-6108 (Linking)
dc.identifier.doi10.3174/ajnr.A4078
dc.identifier.pmid25125666
dc.identifier.urihttp://hdl.handle.net/20.500.14038/48145
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractBACKGROUND AND PURPOSE: Incomplete occlusion and recanalization of large and wide-neck brain aneurysms treated by endovascular therapy remains a challenge. We present preliminary clinical and angiographic results of an experimentally optimized Surpass flow diverter for treatment of intracranial aneurysms in a prospective, multicenter, nonrandomized, single-arm study. MATERIALS AND METHODS: At 24 centers, 165 patients with 190 intracranial aneurysms of the anterior and posterior circulations were enrolled. The primary efficacy end point was the percentage of intracranial aneurysms with 100% occlusion on 6-month DSA. The primary safety end point was neurologic death and any stroke through a minimum follow-up of 6 months. RESULTS: Successful flow-diverter delivery was achieved in 161 patients with 186 aneurysms (98%); the mean number of devices used per aneurysm was 1.05. Clinical follow-up (median, 6 months) of 150 patients (93.2%), showed that the primary safety end point occurred in 18 subjects. Permanent neurologic morbidity and mortality were 6% and 2.7%, respectively. Morbidity occurred in 4% and 7.4% of patients treated for aneurysms of the anterior and posterior circulation, respectively. Neurologic death during follow-up was observed in 1.6% and 7.4% of patients with treated intracranial aneurysms of the anterior and posterior circulation, respectively. Ischemic stroke at 30 days or SAH at >7 days occurred. New or worsening cranial nerve deficit was observed in 2.7%. Follow-up angiography available in 158 (86.8%) intracranial aneurysms showed 100% occlusion in 75%. CONCLUSIONS: Clinical outcomes of the Surpass flow diverter in the treatment of intracranial aneurysms show a safety profile that is comparable with that of stent-assisted coil embolization. Angiographic results showed a high rate of intracranial aneurysm occlusion.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=25125666&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttps://doi.org/10.3174/ajnr.A4078
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.subjectRadiology
dc.titleSurpass flow diverter in the treatment of intracranial aneurysms: a prospective multicenter study
dc.typeJournal Article
dc.source.journaltitleAJNR. American journal of neuroradiology
dc.source.volume36
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/radiology_pubs/252
dc.identifier.contextkey10207184
html.description.abstract<p>BACKGROUND AND PURPOSE: Incomplete occlusion and recanalization of large and wide-neck brain aneurysms treated by endovascular therapy remains a challenge. We present preliminary clinical and angiographic results of an experimentally optimized Surpass flow diverter for treatment of intracranial aneurysms in a prospective, multicenter, nonrandomized, single-arm study.</p> <p>MATERIALS AND METHODS: At 24 centers, 165 patients with 190 intracranial aneurysms of the anterior and posterior circulations were enrolled. The primary efficacy end point was the percentage of intracranial aneurysms with 100% occlusion on 6-month DSA. The primary safety end point was neurologic death and any stroke through a minimum follow-up of 6 months.</p> <p>RESULTS: Successful flow-diverter delivery was achieved in 161 patients with 186 aneurysms (98%); the mean number of devices used per aneurysm was 1.05. Clinical follow-up (median, 6 months) of 150 patients (93.2%), showed that the primary safety end point occurred in 18 subjects. Permanent neurologic morbidity and mortality were 6% and 2.7%, respectively. Morbidity occurred in 4% and 7.4% of patients treated for aneurysms of the anterior and posterior circulation, respectively. Neurologic death during follow-up was observed in 1.6% and 7.4% of patients with treated intracranial aneurysms of the anterior and posterior circulation, respectively. Ischemic stroke at 30 days or SAH at >7 days occurred. New or worsening cranial nerve deficit was observed in 2.7%. Follow-up angiography available in 158 (86.8%) intracranial aneurysms showed 100% occlusion in 75%.</p> <p>CONCLUSIONS: Clinical outcomes of the Surpass flow diverter in the treatment of intracranial aneurysms show a safety profile that is comparable with that of stent-assisted coil embolization. Angiographic results showed a high rate of intracranial aneurysm occlusion.</p>
dc.identifier.submissionpathradiology_pubs/252
dc.contributor.departmentDepartment of Radiology
dc.source.pages98-107


This item appears in the following Collection(s)

Show simple item record